ICH E2C (R2) Periodic benefit-risk evaluation report - Scientific guideline
Table of contents
This document defines the recommended format and content of a periodic benefit-risk evaluation report (PBRER) and provides an outline of points to be considered in its preparation and submission. PBRER is intended to be a common standard for periodic benefit-risk evaluation reporting on marketed products (including approved drugs that are under further study) among the ICH regions. Read together with questions and answers.
Keywords: Periodic benefit-risk evaluation report (PBRER), active substance, fixed dose combination product, efficacy, benefit-risk, periodicity, international birth date, data lock point, reference safety information, cumulative subject exposure, clinical trials, non-interventional studies, medication errors, non-clinical data, literature, late-breaking information, signal, risk
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline E2C (R2) on periodic benefit-risk evaluation report - Step 5 (PDF/476.27 KB)Adopted
First published: 31/12/2012
Last updated: 31/12/2012
Legal effective date: 01/01/2013